| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
2-O-beta-L-galactopyranosylorientin targets inflammatory pathways. It decreases LPS-induced production of nitric oxide (NO), IL-6, and TNF-α in RAW 264.7 cells when used at concentrations ranging from 100 to 200 µM. It is also a substrate of multidrug resistance protein 2 (MRP2). Its mechanism of action involves modulating the production of key inflammatory mediators, thereby reducing the inflammatory response.
|
|---|---|
| ln Vitro |
In vitro, 2-O-beta-L-galactopyranosylorientin decreases LPS-induced production of nitric oxide (NO), IL-6, and TNF-α in RAW 264.7 cells at concentrations of 100 to 200 µM. This demonstrates its potent anti-inflammatory activity in a macrophage cell model. It involves transporter mediated efflux in addition to passive diffusion and is a substrate of MRP2, indicating that its cellular accumulation and activity may be influenced by drug efflux transporters.
|
| ln Vivo |
In vivo activity data for 2-O-beta-L-galactopyranosylorientin is limited in publicly available literature. As a compound with potent anti-inflammatory activity in vitro, it is hypothesized to exhibit similar effects in vivo. However, its status as a substrate of MRP2 suggests that its oral bioavailability and tissue distribution may be limited by active efflux. Specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free assays, the anti-inflammatory activity of 2-O-beta-L-galactopyranosylorientin can be studied by measuring its effect on the activity of inflammatory enzymes, such as iNOS or COX-2, in cell lysates or purified enzyme preparations. Its antioxidant activity can be assessed using DPPH or ABTS radical scavenging assays. Its interaction with MRP2 can be studied using membrane vesicle transport assays or by measuring ATPase activity.
|
| Cell Assay |
For in vitro cellular assays, the anti-inflammatory activity of 2-O-beta-L-galactopyranosylorientin is assessed in LPS-stimulated RAW 264.7 macrophage cells. Cells are treated with varying concentrations of the compound (100-200 µM) prior to or concurrently with LPS stimulation. The production of nitric oxide (NO) is measured using the Griess reagent, and the levels of IL-6 and TNF-α in the culture supernatant are measured by ELISA. Cytotoxicity is assessed using MTT or similar assays.
|
| Animal Protocol |
For in vivo studies, 2-O-beta-L-galactopyranosylorientin could be administered orally or intraperitoneally in animal models of inflammation, such as carrageenan-induced paw edema or LPS-induced sepsis. Its anti-inflammatory effect would be assessed by measuring paw volume, inflammatory cytokine levels, and tissue histopathology. Its pharmacokinetic profile, including the impact of MRP2-mediated efflux on its bioavailability, could be studied.
|
| ADME/Pharmacokinetics |
2-O-beta-L-galactopyranosylorientin (CAS 861691-37-4) has a molecular formula of C27H30O16 and a molecular weight of 610.52 g/mol. Its IUPAC name is 8-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one. Purity is ≥98%. Solubility: DMSO: soluble. Storage: -20°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural flavonoid glycoside from Trollius ledebouri, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability. Its interaction with MRP2 suggests potential for drug-drug interactions.
|
| References |
|
| Additional Infomation |
Reports have indicated that cannabis contains 2"-O-β-L-galactopyranosyl argentin, and relevant data is available for reference.
2-O-beta-L-galactopyranosylorientin is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying inflammation and drug transport. Its mechanism of action involves anti-inflammatory effects through the reduction of NO, IL-6, and TNF-α production. It is a substrate of MRP2, making it useful for studying transporter-mediated efflux. No clinical trials have been reported. |
| Molecular Formula |
C27H30O16
|
|---|---|
| Molecular Weight |
610.5175
|
| Exact Mass |
610.153
|
| CAS # |
861691-37-4
|
| PubChem CID |
14427450
|
| Appearance |
White to yellow solid powder
|
| Density |
1.87
|
| Boiling Point |
988.9±65.0 °C at 760 mmHg
|
| Melting Point |
218-220 ºC
|
| Flash Point |
327.3±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.794
|
| LogP |
-0.99
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
43
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=C(O)C2C(C=C(C3C=CC(O)=C(O)C=3)OC=2C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)=O
|
| InChi Key |
QQBFHNKJGBCSLG-KLYXJHKJSA-N
|
| InChi Code |
InChI=1S/C27H30O16/c28-6-15-20(36)22(38)26(43-27-23(39)21(37)19(35)16(7-29)42-27)25(41-15)18-12(33)4-11(32)17-13(34)5-14(40-24(17)18)8-1-2-9(30)10(31)3-8/h1-5,15-16,19-23,25-33,35-39H,6-7H2/t15-,16+,19-,20-,21-,22+,23+,25+,26-,27-/m1/s1
|
| Chemical Name |
8-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~163.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6379 mL | 8.1897 mL | 16.3795 mL | |
| 5 mM | 0.3276 mL | 1.6379 mL | 3.2759 mL | |
| 10 mM | 0.1638 mL | 0.8190 mL | 1.6379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
